Trials / Withdrawn
WithdrawnNCT04840927
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
An Open-Label, Single Center, Randomized, Pharmacoscintigraphic Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release Tablets Compared to an E7386 Immediate Release Tablet in Healthy Adult Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7386 | Regimen A: 40 milligram (mg) IR Oral Tablet. |
Timeline
- Start date
- 2021-04-09
- Primary completion
- 2023-05-17
- Completion
- 2023-05-17
- First posted
- 2021-04-12
- Last updated
- 2023-11-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04840927. Inclusion in this directory is not an endorsement.